S&P 500
(0.55%) 5 155.86 points
Dow Jones
(0.10%) 38 714 points
Nasdaq
(0.67%) 16 265 points
Oil
(0.60%) $78.58
Gas
(4.06%) $2.23
Gold
(0.89%) $2 329.10
Silver
(3.18%) $27.54
Platinum
(-0.20%) $963.40
USD/EUR
(-0.09%) $0.928
USD/NOK
(-0.41%) $10.83
USD/GBP
(-0.20%) $0.795
USD/RUB
(-0.11%) $91.35

के लिए वास्तविक समय के अद्यतन Grifols, S.A. [GIKLY]

एक्सचेंज: OTC क्षेत्र: Healthcare उद्योग: Drug Manufacturers—General
अंतिम अद्यतन6 May 2024 @ 19:00

3.52% $ 5.00

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 19:00):

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions...

Stats
आज की मात्रा 300.00
औसत मात्रा 3 296.00
बाजार मूल्य 5.92B
EPS $0 ( 2023-09-30 )
अगली कमाई की तारीख ( $0 ) 2024-06-14
Last Dividend $0.222 ( 2021-06-03 )
Next Dividend $0 ( N/A )
P/E 100.00
ATR14 $0 (0.00%)

Grifols, S.A. सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Grifols, S.A. वित्तीय

Annual 2023
राजस्व: $6.59B
सकल लाभ: $2.32B (35.24 %)
EPS: $0.0873
FY 2023
राजस्व: $6.59B
सकल लाभ: $2.32B (35.24 %)
EPS: $0.0873
FY 2022
राजस्व: $6.06B
सकल लाभ: $2.23B (36.80 %)
EPS: $0.310
FY 2021
राजस्व: $4.93B
सकल लाभ: $1.96B (39.78 %)
EPS: $0.133

Financial Reports:

No articles found.

Grifols, S.A. Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Grifols, S.A. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 5.88 - average (63.08%) | Divividend Growth Potential Score: 2.52 - No dividend growth expected in the near future
Information
First Dividend $0.0385 2010-06-28
Last Dividend $0.222 2021-06-03
Next Dividend $0 N/A
Payout Date 2021-06-14
Next Payout Date N/A
# dividends 16 --
Total Paid Out $1.516 --
Avg. Dividend % Per Year 0.00% --
Score 1.92 --
Div. Sustainability Score 5.88
Div.Growth Potential Score 2.52
Div. Directional Score 4.20 --
Next Divdend (Est)
(2024-06-20)
$0 Estimate 0.00 %
Dividend Stability
0.06 Very Bad
Dividend Score
1.92
Pay Frequency
Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
PUMSY Ex Dividend Junior 2023-05-25 Annually 0 0.00%
ECTM Ex Dividend Junior 2023-05-19 Quarterly 0 0.00%
WAKE Ex Dividend Knight 2023-10-03 Quarterly 0 0.00%
KKOYY Ex Dividend Junior 2023-09-11 Semi-Annually 0 0.00%
BTLCY Ex Dividend Junior 2023-06-22 Semi-Annually 0 0.00%
SCVPY Ex Dividend Junior 2023-08-08 Semi-Annually 0 0.00%
FINN Ex Dividend Knight 2023-08-07 Bi-Monthly 0 0.00%
MLGF Ex Dividend Knight 2023-09-21 Quarterly 0 0.00%
CLPBY Ex Dividend Junior 2023-05-19 Semi-Annually 0 0.00%
SUOPY Ex Dividend Junior 2023-06-29 Sporadic 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.02511.5009.5010.00[0 - 0.5]
returnOnAssetsTTM0.007691.2009.7410.00[0 - 0.3]
returnOnEquityTTM0.02791.500-0.801-1.202[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM2.790.8001.0690.855[1 - 3]
quickRatioTTM0.6290.800-1.006-0.805[0.8 - 2.5]
cashRatioTTM0.2291.5009.8410.00[0.2 - 2]
debtRatioTTM0.425-1.5002.92-4.38[0 - 0.6]
interestCoverageTTM2.331.000-0.248-0.248[3 - 30]
operatingCashFlowPerShareTTM0.3072.009.9010.00[0 - 30]
freeCashFlowPerShareTTM-0.05382.00-0.0269-0.0538[0 - 20]
debtEquityRatioTTM1.564-1.5003.74-5.62[0 - 2.5]
grossProfitMarginTTM0.3811.0006.996.99[0.2 - 0.8]
operatingProfitMarginTTM0.1351.0009.309.30[0.1 - 0.6]
cashFlowToDebtRatioTTM0.02291.000-0.984-0.984[0.2 - 2]
assetTurnoverTTM0.3060.800-1.291-1.033[0.5 - 2]
Total Score5.88

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM18.471.0008.240[1 - 100]
returnOnEquityTTM0.02792.50-0.515-1.202[0.1 - 1.5]
freeCashFlowPerShareTTM-0.05382.00-0.0179-0.0538[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM0.3072.009.9010.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.8841.5007.440[0.5 - 2]
operatingCashFlowSalesRatioTTM0.03171.000-1.7080[0.1 - 0.5]
Total Score2.52

Grifols, S.A.

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

के बारे में लाइव सिग्नल्स

इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।

लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं